Colorectal cancer is the second leading cause of cancer deaths in the United States. When localized to the mucosa and submucosa of the bowel wall (Stage I), the five year survival approaches 100%;however, metastasis to lymph nodes (Stage 111) results in a precipitous decrease in five year survival and systemic metastasis to the liver (ie, Stage IV) is associated with a five year survival that is less than 5%. Activation of phosphatidylinositol 3-kinase (PI3K), a ubiquitous lipid kinase composed of an 85 kDa regulatory subunit (p85) and a 110 kDa catalytic subunit (p110), and its downstream effector protein, Akt, is associated with the growth and progression of a number of cancers, including colorectal cancer. We have shown that inhibition of PISK/Akt decreases viability and growth, increases differentiation and apoptosis of human colorectal cancer cells. Furthermore, PISK/Akt inhibition decreases colon cancer xenograft growth in athymic nude mice and sensitizes these cancers to the apoptotic effects of chemotherapeutic agents (eg, 5- FU). Moreover, we have shown altered PISK/Akt expression in colorectal cancers and surrounding stroma with increased expression of the p8Sa subunit and Akt2 in colorectal cancers of increasing stage. Targeted inhibition of either p8Sa or p110a by RNA interference (RNAi) increased sensitivity of resistant colorectal cancers to the effects of chemotherapy and significantly suppressed colorectal cancer metastasis to the liver in preclinical animal models. The central hypothesis of this project is that colorectal cancer growth and progression are augmented by increased p85a and Akt2 expression;the selective inhibition of PISK/Akt components can suppress colorectal cancer growth and metastasis and can sensitize resistant colorectal cancers to chemotherapeutic agents. The long-term qoai is to develop more selected therapies for colorectal cancer progression and metastasis based on a systematic analysis of colorectal cancers, tumor stroma and surrounding mucosa for expression of piSK/Akt pathway components. To examine our hypothesis and address the long-term goal, we have designed experiments with the following Specific Aims: 1) To provide clinical validation of the pattern and significance of PISK/Akt/PTEN pathway component expression in polyps and colorectal cancers of different stages. 2) To assess novel strategies of selective PISK component inhibition on in vivo tumor growth and liver metastasis using preclinical animal models. 3) To evaluate the therapeutic efficacy of RNAi to the PISK pathway in combination with conventional chemotherapy. The cumulative information derived from ttiese studies will lead to better targeted therapeutics and treatment paradigms for colorectal cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Exploratory Grants (P20)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (O1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Kentucky
United States
Zip Code
Yu, T; Chen, X; Lin, T et al. (2016) KLF4 deletion alters gastric cell lineage and induces MUC2 expression. Cell Death Dis 7:e2255
Yamane, Daisuke; McGivern, David R; Wauthier, Eliane et al. (2014) Regulation of the hepatitis C virus RNA replicase by endogenous lipid peroxidation. Nat Med 20:927-35
Ye, Q; Cai, W; Zheng, Y et al. (2014) ERK and AKT signaling cooperate to translationally regulate survivin expression for metastatic progression of colorectal cancer. Oncogene 33:1828-39
Zaytseva, Yekaterina Y; Elliott, Victoria A; Rychahou, Piotr et al. (2014) Cancer cell-associated fatty acid synthase activates endothelial cells and promotes angiogenesis in colorectal cancer. Carcinogenesis 35:1341-51
Valentino, Joseph D; Li, Jing; Zaytseva, Yekaterina Y et al. (2014) Cotargeting the PI3K and RAS pathways for the treatment of neuroendocrine tumors. Clin Cancer Res 20:1212-22
Wang, Q; Zhou, Y; Rychahou, P et al. (2013) NFAT5 represses canonical Wnt signaling via inhibition of ?-catenin acetylation and participates in regulating intestinal cell differentiation. Cell Death Dis 4:e671
Valentino, Joseph D; Rychahou, Piotr G; Mustain, W Conan et al. (2013) Murine portal vein catheterization to analyze liver-directed therapies. J Surg Res 185:690-6
Li, X; Stevens, P D; Yang, H et al. (2013) The deubiquitination enzyme USP46 functions as a tumor suppressor by controlling PHLPP-dependent attenuation of Akt signaling in colon cancer. Oncogene 32:471-8
Zhang, Wen; Sviripa, Vitaliy; Chen, Xi et al. (2013) Fluorinated N,N-dialkylaminostilbenes repress colon cancer by targeting methionine S-adenosyltransferase 2A. ACS Chem Biol 8:796-803
Kim, Seungtaek; Ishida, Hisashi; Yamane, Daisuke et al. (2013) Contrasting roles of mitogen-activated protein kinases in cellular entry and replication of hepatitis C virus: MKNK1 facilitates cell entry. J Virol 87:4214-24

Showing the most recent 10 out of 30 publications